Bafna Pharmaceuticals
Bafna Pharmaceuticals Performance
Day Range
- Low 87.80
- High 90.95
52 Week Range
- Low 77.05
- High 124.45
- Open Price88.80
- Previous Close87.70
- Volume8442
Start SIP in Bafna Pharmaceuticals
Start SIPBafna Pharmaceuticals Investment Rating
-
Master Rating:
-
Bafna Pharmaceuticals has an operating revenue of Rs. 159.09 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 10% is healthy, ROE of 15% is good. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 28% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 9 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 41 | 42 | 42 | 34 | 22 | 17 | 15 |
Operating Expenses Qtr Cr | 37 | 36 | 35 | 31 | 19 | 15 | 16 |
Operating Profit Qtr Cr | 4 | 6 | 8 | 4 | 3 | 2 | -1 |
Depreciation Qtr Cr | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
Interest Qtr Cr | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Profit Qtr Cr | 2 | 6 | 5 | 3 | 2 | 1 | -1 |
Bafna Pharmaceuticals Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 11
- Bearish Moving Average
- ___
- 5
- 20 Day
- ₹86.74
- 50 Day
- ₹88.13
- 100 Day
- ₹90.08
- 200 Day
- ₹94.24
- 20 Day
- ₹85.64
- 50 Day
- ₹88.98
- 100 Day
- ₹90.59
- 200 Day
- ₹92.86
Bafna Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 91.07 |
Second Resistance | 92.58 |
Third Resistance | 94.22 |
RSI | 55.72 |
MFI | 74.92 |
MACD Single Line | -0.54 |
MACD | 0.23 |
Support | |
---|---|
First Resistance | 87.92 |
Second Resistance | 86.28 |
Third Resistance | 84.77 |
Bafna Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 8,776 | 877,600 | 100 |
Week | 31,770 | 3,177,025 | 100 |
1 Month | 17,127 | 1,712,681 | 100 |
6 Month | 6,813 | 681,285 | 100 |
Bafna Pharmaceuticals Result Highlights
Bafna Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Bafna Pharmaceutical belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 115.35 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2023. Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698.Market Cap | 212 |
Sales | 159 |
Shares in Float | 0.26 |
No of funds | |
Yield |
Book Value | 2.88 |
U/D Vol ratio | 0.5 |
LTDebt / Equity | 11 |
Alpha | -0.03 |
Beta | 0.07 |
Bafna Pharmaceuticals
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 88.74% | 90% | 90% | 90.02% |
Foreign Portfolio Investors | ||||
Individual Investors | 6.87% | 5.64% | 5.63% | 5.61% |
Others | 4.39% | 4.36% | 4.37% | 4.37% |
Bafna Pharmaceuticals Management
Name | Designation |
---|---|
Mrs. S Hemalatha | Chairperson & Executive Director |
Mrs. Akila C Raju | Non Exe.Non Ind.Director |
Ms. R Chitra | Ind. Non-Executive Director |
Mr. B Kamlesh Kumar | Ind. Non-Executive Director |
Mr. P K Sundaresan | Ind. Non-Executive Director |
Bafna Pharmaceuticals Forecast
Price Estimates
Bafna Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-09 | Quarterly Results | |
2023-08-11 | Quarterly Results | |
2023-05-27 | Audited Results | (Revised) |
2023-04-07 | Others | |
2023-02-08 | Quarterly Results |
Bafna Pharmaceuticals FAQs
What is Share Price of Bafna Pharmaceuticals ?
Bafna Pharmaceuticals share price is ₹89 As on 03 December, 2023 | 07:29
What is the Market Cap of Bafna Pharmaceuticals ?
The Market Cap of Bafna Pharmaceuticals is ₹211.8 Cr As on 03 December, 2023 | 07:29
What is the P/E ratio of Bafna Pharmaceuticals ?
The P/E ratio of Bafna Pharmaceuticals is 12.3 As on 03 December, 2023 | 07:29
What is the PB ratio of Bafna Pharmaceuticals ?
The PB ratio of Bafna Pharmaceuticals is 2.9 As on 03 December, 2023 | 07:29